\-\ Texto\\:\\ \ \(0\)\
\-\ first\\-line\\ therapy\\ for\\ patients\\ with\\ adpkd\\ typically\\ involves\\ controlling\\ hypertension\\.\\ \\ treating\\ hypertension\\ appears\\ to\\ serve\\ two\\ functions\\.\\ \\ the\\ first\\ is\\ to\\ slow\\ the\\ rate\\ of\\ loss\\ of\\ renal\\ function\\.\\ \\ the\\ second\\ is\\ with\\ controlled\\ hypertension\\ the\\ risk\\ of\\ a\\ rupturing\\ a\\ \\ cerebral\\ aneurysm\\ \\(which\\ these\\ patients\\ are\\ predisposed\\ to\\)\\ \\ is\\ decreased\\.\\ \\ \\ ace\\ inhibitors\\ are\\ currently\\ the\\ anti\\-hypertensive\\ medication\\ of\\ choice\\.\\ \\ patients\\ that\\ develop\\ end\\-stage\\ renal\\ disease\\ will\\ ultimately\\ need\\ dialysis\\ or\\ kidney\\ transplant\\.\ \(0\)\
\-\ multiple\\ bilateral\\ renal\\ cysts\\ consistent\\ with\\ the\\ diagnosis\\ of\\ adult\\ polycystic\\ kidney\\ disease\ \(0\)\
\-\ autosomal\\ dominant\\ \\(adult\\)\\ polycystic\\ kidney\\ disease\\ \\(adpkd\\)\ \(0\)\
\-\ adult\\ polycystic\\ kidney\\ disesase\ \(0\)\
\-\ cystic\\ renal\\ dysplasia\ \(5\)\
\-\ nephronophthisis\ \(0\)\
\-\ acquired\\ cystic\\ kidney\\ disease\ \(0\)\
\-\ 26\\ year\\ of\\ african\\ american\\ male\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ polycystic\\:\\ 0\\.1232760562993399\ \(0\)\
\-\ kidney\\:\\ 0\\.1223733111808947\ \(0\)\
\-\ adult\\:\\ 0\\.10446143733690835\ \(0\)\
\-\ adpkd\\:\\ 0\\.09727325333187452\ \(0\)\
\-\ renal\\:\\ 0\\.08349513981977462\ \(0\)\
\-\ hypertension\\:\\ 0\\.08216539151951678\ \(0\)\
\-\ disesase\\:\\ 0\\.0716708814956626\ \(0\)\
\-\ rupturing\\:\\ 0\\.06603553856428092\ \(0\)\
\-\ nephronophthisis\\:\\ 0\\.06603553856428092\ \(0\)\
\-\ anti\\-hypertensive\\:\\ 0\\.0627390742707186\ \(0\)\
\-\ serve\\:\\ 0\\.06040019563289926\ \(0\)\
\-\ first\\-line\\:\\ 0\\.05858602041896259\ \(0\)\
\-\ functions\\:\\ 0\\.05476485270151758\ \(0\)\
\-\ patients\\:\\ 0\\.053940843886976245\ \(0\)\
\-\ controlling\\:\\ 0\\.053807267045774626\ \(0\)\
\-\ inhibitors\\:\\ 0\\.05146838840795527\ \(0\)\
\-\ predisposed\\:\\ 0\\.05021513084838407\ \(0\)\
\-\ end\\-stage\\:\\ 0\\.0496542131940186\ \(0\)\
\-\ ace\\:\\ 0\\.04863662666593726\ \(0\)\
\-\ disease\\:\\ 0\\.04542235906392534\ \(0\)\
\-\ dialysis\\:\\ 0\\.04349416683875424\ \(0\)\
\-\ treating\\:\\ 0\\.04300128373455559\ \(0\)\
\-\ controlled\\:\\ 0\\.04167999162481758\ \(0\)\
\-\ ultimately\\:\\ 0\\.040543715670548\ \(0\)\
\-\ autosomal\\:\\ 0\\.040197702545191935\ \(0\)\
\-\ cystic\\:\\ 0\\.04007532857319933\ \(0\)\
\-\ transplant\\:\\ 0\\.038383527331255274\ \(0\)\
\-\ slow\\:\\ 0\\.037608647820651\ \(0\)\
\-\ acquired\\:\\ 0\\.03724725137698568\ \(0\)\
\-\ african\\:\\ 0\\.03625048453070656\ \(0\)\
\-\ choice\\:\\ 0\\.035943652595886666\ \(0\)\
\-\ dominant\\:\\ 0\\.03545667583506496\ \(0\)\
\-\ medication\\:\\ 0\\.03499722697113536\ \(0\)\
\-\ develop\\:\\ 0\\.03464749213305657\ \(0\)\
\-\ need\\:\\ 0\\.03464749213305657\ \(0\)\
\-\ american\\:\\ 0\\.033094197525229664\ \(0\)\
\-\ involves\\:\\ 0\\.032287246646405754\ \(0\)\
\-\ 26\\:\\ 0\\.032160211541502656\ \(0\)\
\-\ function\\:\\ 0\\.029451720106311287\ \(0\)\
\-\ currently\\:\\ 0\\.02752986012204925\ \(0\)\
\-\ aneurysm\\:\\ 0\\.027458854593847993\ \(0\)\
\-\ dysplasia\\:\\ 0\\.027423583036135814\ \(0\)\
\-\ cysts\\:\\ 0\\.02721510799049892\ \(0\)\
\-\ rate\\:\\ 0\\.027079036507933685\ \(0\)\
\-\ second\\:\\ 0\\.026683975083243727\ \(0\)\
\-\ appears\\:\\ 0\\.025859583908920722\ \(0\)\
\-\ risk\\:\\ 0\\.025164281685846234\ \(0\)\
\-\ typically\\:\\ 0\\.024523786743950997\ \(0\)\
\-\ cerebral\\:\\ 0\\.024068670746049358\ \(0\)\
\-\ first\\:\\ 0\\.023312873453543517\ \(0\)\
\-\ will\\:\\ 0\\.021735618035602783\ \(0\)\
\-\ decreased\\:\\ 0\\.02065655611971187\ \(0\)\
\-\ loss\\:\\ 0\\.020166375385922274\ \(0\)\
\-\ two\\:\\ 0\\.019897001931837445\ \(0\)\
\-\ are\\:\\ 0\\.018941038577717104\ \(0\)\
\-\ therapy\\:\\ 0\\.01857431541659035\ \(0\)\
\-\ these\\:\\ 0\\.018080038145998702\ \(0\)\
\-\ \\(\\:\\ 0\\.017618578688874648\ \(0\)\
\-\ \\)\\:\\ 0\\.017403358344226953\ \(0\)\
\-\ consistent\\:\\ 0\\.017034945275050433\ \(0\)\
\-\ bilateral\\:\\ 0\\.016860306742393857\ \(0\)\
\-\ diagnosis\\:\\ 0\\.015953002689271707\ \(0\)\
\-\ multiple\\:\\ 0\\.014632569133977797\ \(0\)\
\-\ is\\:\\ 0\\.013714409228895748\ \(0\)\
\-\ which\\:\\ 0\\.01296865518083373\ \(0\)\
\-\ male\\:\\ 0\\.012562646649491653\ \(0\)\
\-\ that\\:\\ 0\\.011999843321616452\ \(0\)\
\-\ to\\:\\ 0\\.010416295327877714\ \(0\)\
\-\ or\\:\\ 0\\.008142461373688679\ \(0\)\
\-\ year\\:\\ 0\\.0077732135713245104\ \(0\)\
\-\ the\\:\\ 0\\.006743867546518332\ \(0\)\
\-\ a\\:\\ 0\\.0064487772653431105\ \(0\)\
\-\ for\\:\\ 0\\.00592770852555053\ \(0\)\
\-\ of\\:\\ 0\\.005683112234048216\ \(0\)\
\-\ with\\:\\ 0\\.002853760392436335\ \(0\)\
\-\ \\.\\:\\ 0\\.0017316846876754281\ \(0\)\
